BIOFILCHEM2025-10-012025-12-31BIOFILCHEM2025-12-31BIOFILCHEM2025-04-012025-12-31BIOFILCHEM2025-10-012025-12-31in-capmkt:OtherExpenses1MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:OtherExpenses2MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:OtherExpenses3MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:OtherExpenses1MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:OtherExpenses2MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:OtherExpenses3MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-04-012025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-12-31in-capmkt:ReportableSegments1MemberBIOFILCHEM2025-10-012025-12-31in-capmkt:ReportableSegments2MemberBIOFILCHEM2025-12-31in-capmkt:ReportableSegments2Memberiso4217:INRiso4217:INRxbrli:shares524396BIOFILCHEMNOTLISTEDINE829A01014BIOFIL CHEMICALS & PHARMACEUTICALS LIMITEDMain BoardEquity2025-04-012026-03-312026-02-132026-02-03INRLakhsQuarterlyThird quarterMulti segment2026-02-1315:30:002026-02-1316:20:00Not applicablefalsefalseNot Applicable2025-10-012025-12-31UnauditedStandalone85630007830009346000323150000-2880300019130005000660000218900082790001067000010670002750000275000079200000007920000792000162738000100.050.05000.050.051. The above unaudited financial results for the Quarter and nine month ended December 31, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on February 13, 2026. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs. <BR> <BR> 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. <BR> <BR> 3. The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments <BR> a. Pharma Division <BR> b. Chemicals Division. <BR> <BR> 4. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary. <BR> <BR> 5.The aforesaid un-audited financial Results will be uploaded on the Company’s website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.Further Publication contaning a Quick Response Code and the details of the webpage where complete financial results of the company are available will be published in english and hindi newspapers within prescribed time limit. <BR> <BR> 6. Due to the revision in Schedule M (Drugs & Cosmetics Rules), the factory is presently undergoing renovation and upgradation work, therefore manufacturing operations were partially disrupted during the quarter, resulting in a decline in turnover as compared to the previous quarter.2025-04-012025-12-31UnauditedStandalone2082960002973800023803400055848000168152000-302140005797000990001980000656500020822700029807000029807000407000004070000025737000000025737000025737000162738000101.581.58001.581.58Manufacturing Expenses738000Administrative Expenses1422000Selling and Distribution Expenses29000Manufacturing Expenses2702000Administrative Expenses3538000Selling and Distribution Expenses325000Pharma Unit8563000Chemicals Division0Pharma Unit178485000Chemicals Division2981100085630002082960008563000208296000Pharma Unit-1045000Chemicals Division1673000Pharma Unit26652000Chemicals Division245400062800029106000-439000-701000106700029807000Pharma Unit386079000Chemicals Division1692660005553450000555345000Pharma Unit316257000Chemicals Division255350003417920000341792000000000